Figure 2. Change in 24h proteinuria, serum creatinine and hematuria from baseline over the Nefecon treatment phase and follow-up phase.Scr, serum creatinine.RBC, red blood cells.HPF, high power field.Conclusion: This is the first reported case of pediatric IgAN treated with Nefecon (TRF-budesonide).The 9-month Nefecon therapy effectively reduced proteinuria/hematuria and preserved renal function, with minimal side effects (only facial acne).A 6-month follow-up confirmed sustained benefits with Benazepril alone.These findings suggest Nefecon may be a safe and effective option for pediatric IgAN, but further large-scale studies are needed to confirm long-term safety, optimal dosing, and efficacy across diverse pediatric populations.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Randhay et al. (Wed,) studied this question.